Myuri Ruthirakuhan1, Krista L Lanctôt2, Matteo Di Scipio3, Mehnaz Ahmed1, Nathan Herrmann4. 1. Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. 2. Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Geriatric Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 3. Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada. 4. Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada; Geriatric Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address: nathan.herrmann@sunnybrook.ca.
Abstract
INTRODUCTION: Agitation is one of the most challenging neuropsychiatric symptoms to treat in Alzheimer's disease and has significant implications for patient and caregiver. A major source of difficulty in identifying safe and effective treatments for agitation is the lack of validated biomarkers. As such, patients may not be appropriately targeted, and biological response to pharmacotherapy cannot be adequately monitored. METHODS: This systematic review aimed to summarize evidence on the association between biomarkers and agitation/aggression in patients with Alzheimer's disease, utilizing the National Institute on Aging-Alzheimer's Association Research Framework and the Biomarkers, EndpointS, and other Tools Resource of the Food and Drug Association-National Institutes of Health Biomarker Working Group. RESULTS: This review identified six classes of biomarkers (neuropathological, neurotransmitter, neuroimaging, apolipoprotein E (APOE) genotype, inflammatory, and clusterin) associated with agitation/aggression, which were mostly diagnostic in nature. DISCUSSION: Future studies should investigate the predictive, prognostic, and monitoring capacity of biomarkers to provide insight into the longitudinal course of agitation/aggression, as well as predict and monitor biological response to a pharmacological intervention.
INTRODUCTION:Agitation is one of the most challenging neuropsychiatric symptoms to treat in Alzheimer's disease and has significant implications for patient and caregiver. A major source of difficulty in identifying safe and effective treatments for agitation is the lack of validated biomarkers. As such, patients may not be appropriately targeted, and biological response to pharmacotherapy cannot be adequately monitored. METHODS: This systematic review aimed to summarize evidence on the association between biomarkers and agitation/aggression in patients with Alzheimer's disease, utilizing the National Institute on Aging-Alzheimer's Association Research Framework and the Biomarkers, EndpointS, and other Tools Resource of the Food and Drug Association-National Institutes of Health Biomarker Working Group. RESULTS: This review identified six classes of biomarkers (neuropathological, neurotransmitter, neuroimaging, apolipoprotein E (APOE) genotype, inflammatory, and clusterin) associated with agitation/aggression, which were mostly diagnostic in nature. DISCUSSION: Future studies should investigate the predictive, prognostic, and monitoring capacity of biomarkers to provide insight into the longitudinal course of agitation/aggression, as well as predict and monitor biological response to a pharmacological intervention.
Authors: Ganesh M Babulal; Ling Chen; Jason M Doherty; Samantha A Murphy; Ann M Johnson; Catherine M Roe Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Kristen D Onos; Asli Uyar; Kelly J Keezer; Harriet M Jackson; Christoph Preuss; Casey J Acklin; Rita O'Rourke; Rebecca Buchanan; Travis L Cossette; Stacey J Sukoff Rizzo; Ileana Soto; Gregory W Carter; Gareth R Howell Journal: PLoS Genet Date: 2019-05-31 Impact factor: 5.917
Authors: Myuri Ruthirakuhan; Nathan Herrmann; Ana C Andreazza; Nicolaas Paul L G Verhoeff; Damien Gallagher; Sandra E Black; Alex Kiss; Krista L Lanctôt Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Kathy Y Liu; Anya Borissova; Jansher Mahmood; Thomas Elliott; Melanie Knowles; Peter Bentham; Suzanne Reeves; Robert Howard Journal: Alzheimers Dement (N Y) Date: 2021-03-30